Navigation Links
Fuse Science Announces the Launch of its Analgesic and Diabetic Oral Fuse Delivery (OFD) Research Project Platforms
Date:12/20/2011

AVENTURA, Fla., Dec. 20, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd. (OTCQB: DROP), the parent company of Fuse Science, Inc. (www.fusescience.com), announced today the formal launch of its Hypoglycemic, Hyperglycemic, and  Analgesic project platforms for the advancement of its OTC and pharmaceutical licensing efforts.  

Some of the proprietary science platforms that Fuse Science deals with are oral fuse delivery technologies (OFD's). These OFD's are placed under the tongue or in the inner cheek of the patient where they are absorbed and release the applicable active or nutrient into the blood stream.  OFD's do not require water and may be more convenient to take than liquids or injections.  OFD's are especially designed to be very useful with pediatric and geriatric patients or anyone in need of faster absorption of a given active into the blood stream that bypasses the GI track, providing an alternative to the more traditional invasive drug delivery systems.

"Today we announce the further advancement of the true core of our Powered by Fuse™ technology," said Brian Tuffin, Fuse Science Chief Executive Officer. "It is with high confidence that we advance our OFD Analgesic, Hypoglycemic and Hyperglycemic project platforms with the objective of completing our pediatric and adult formulations to provide an effective sublingual and/or Buccal delivery alternative for the respective drugs."

The business opportunities from these project platforms are as follows:

  • The side effects of aspirin on the stomach include bleeding of the abdomen and deterioration of the stomach lining.  By bypassing the GI track with our drop technology we intend to improve performance and usage in the $2.5 billion adult analgesic category.
  • The largest disease state globally is diabetes with an estimated 285 million people, corresponding to 6.4% of the world's adult population living with diabetes in 2010. The number is expected to grow to 438 million by 2030, or 7.8% of the adult population. . One major issue associated with the treatment of diabetes is lack of compliance. The ease of use associated with the OFD will help address the major compliance issues in this $25 billion dollar treatment category worldwide.

"We are extremely passionate about our work in this area," said Ed Maliski, Ph.D. & Lead scientist. "Our work is born out of diabetes sufferers on staff who are committed to advancing these platforms with sense of urgency. We have produced significant results with our OFD work and feel very confident at this stage with our ability to advance these project platforms."

"We continue to be very deliberate and focused with every step we take as a company and our efforts in the OTC and Pharmaceutical space represents the foundation to our long term focus," added Tuffin.  "These actions in combination with the with the long awaited, Powered by Fuse™ EnerJel™ launch on December 30th, 2011 at www.poweredbyfuse.com are calculated steps in our effort to create long term shareholder value."

About Double Eagle Holdings
Double Eagle Holdings (OTCQB: DROP) is the parent company of Fuse Science, Inc., an innovative consumer products holding company based in Aventura, Florida.  The corporate name, Double Eagle Holdings is in the process of being changed to Fuse Science Inc.  Fuse Science is the developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.  The company has successfully developed and maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly – all in a concentrated "DROP" form that is simply applied under the tongue.  The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products.  Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.



'/>"/>
SOURCE Double Eagle Holdings
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
8. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/27/2017)... March 27, 2017 The National University ... and data analytics company, signed a Memorandum of ... healthcare delivery in the region. ... Health Research and Technology (BIGHEART) at NUS and ... topics related to healthcare IT and medical device ...
(Date:3/27/2017)... , March 27, 2017 ... better understand Eli Lilly and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning ... will begin serving as new board chair for Orange County health care system ... the remainder of soon-to-be former chair Mark Refowitz’s term, which runs through June ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ... Success website has recently developed and published an informational resource that addresses frequently ... based on common inquiries the site’s team of third party administrator (TPA) contributors ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... skin is a common and unwelcomed occurrence in people of all ages, genders and ethnicities. ... the discussion of dealing with excess skin oil. “Oily skin is a challenge to many ... help remove the oily shine while keeping the skin fresh and clean,” says Dr. Au. ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep ... apnea treatment, with or without a referral. Sleep apnea is often left untreated because ... sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness ...
Breaking Medicine News(10 mins):